Boardroom Alpha
Start trial
10-K primary document
RPRX · Annual Report (Form 10-K) · Filed February 11, 2026

Royalty Pharma PLC — 10-K exhibit

rprx-20251231ex1031.htm
Royalty Pharma PLC on Boardroom Alpha
Document
ex31_1x01.jpg


December 31, 2025



CONFIDENTIAL



Dear George:

    Reference is made to the Offer Letter dated May 16, 2025 between Royalty Pharma LLC (the “Company”) and you (the “Offer Letter”). By mutual agreement, the Offer Letter is hereby terminated effective at 11:59pm (Eastern Time) on December 31, 2025 and your employment with the Company will continue thereafter on the terms set forth herein.

Position: Senior Adviser, reporting to the Chief Executive Officer.

Dedication of Time: It is our expectation that you will work at least half time on Company matters.

Base Salary: Your annual base salary will be $700,000. Your annual salary will be paid less applicable deductions and withholdings, and will be payable pursuant to the Company’s normal payroll practices.

Bonus: You will not be entitled to any bonus.

Employment at Will: Your employment with the Company will be on an at-will basis and is not guaranteed for any specific term. Your employment may be terminated at any time by the Company, with or without prior notice and for any reason or no reason.

Benefits: You will be entitled to participate in such employee benefit plans as are made available to other employees at the Company on the same terms and conditions as may be applicable from time to time to such employees. At a minimum, you will be eligible to participate in the Company’s health, dental, vision and 401(k) plans, subject to the terms and conditions of those plans. All benefit plans may be amended at any time by the Company or plan sponsors in their sole discretion.



ex31_1x02.jpg

Other Agreements: Reference is made to the Confidentiality, Non-Solicitation and Non-Competition Agreement dated September 25, 2023 between the Company (in its capacity as the successor to RP Management, LLC) and you. The terms of such agreement will continue in effect in accordance with its terms. Neither the termination of the Offer Letter nor this letter agreement shall alter any other contract between you and any affiliate of the Company.

Very truly yours,
Royalty Pharma, LLC
By: /s/ Pablo Legorreta
Pablo Legorreta
Chief Executive Officer


AGREED AND ACCEPTED:



/s/ George W. Lloyd
George W. Lloyd
Date: December 31, 2025


2

Disclaimer

The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.

This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.

None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.

No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.

Full disclaimer